摘要
目的探讨疏风解毒胶囊免疫调节作用机制。方法采用肺炎链球菌致肺炎大鼠模型,观察疏风解毒胶囊给药后对淋巴细胞分类,细胞因子白细胞介素-1α(IL-1α)、IL-1β、IL-2、IL-4、IL-6、IL-10、肿瘤坏死因子-α(TNF-α)、α干扰素(IFN-α)、γ干扰素(IFN-γ)水平,免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)水平,胸腺、脾脏、肺脏质量的影响。结果疏风解毒胶囊能显著降低模型大鼠外周血B淋巴细胞比例、CD8+比例,降低血清IL-1α、IL-1β、IL-2、IL-10、TNF-α、IFN-α、IFN-γ、IgM、IgG水平,降低肺炎大鼠胸腺、脾脏、肺脏质量,升高外周血CD4+/CD8+及NK细胞比例。结论疏风解毒胶囊有显著的免疫调节作用,其通过降低B淋巴细胞、CD8+比例及IL-1α、IL-1β、IL-2、IL-10、TNF-α、IFN-α、IFN-γ、IgM、IgG水平,降低肺炎大鼠胸腺、脾脏、肺脏质量,升高CD4+/CD8+及NK细胞比例对肺炎模型大鼠有显著的治疗作用。
Objective To explore the immunoregulation of Shufeng Jiedu Capsule(SJC)and its mechanism.Methods Using the Streptococcus pneumoniae(SP)-induced pneumonia rats model to study the immunoregulation of SJC,collecting peripheral blood and serum to measure the factors related to immune response such as lymphocyte classification,interleukin-1α(IL-1α),interleukin-1β(IL-1β),interleukin-2(IL-2),interleukin-4(IL-4),interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor(TNF-α),interferon-α(IFN-α),interferon-γ(IFN-γ),immunoglobulin A(IgA),immunoglobulin M(IgM),immunoglobulin G(IgG),and the weight of thymus,spleen and lung.Results SJC can significantly decrease B cell(%)and CD8+(%)in peripheral blood,decrease the levels of IL-1α,IL-1β,IL-2,IL-10,TNF-α,IFN-α,IFN-γ,IgM,and IgG in serum,reduce the weight of thymus,spleen,and lung.It also increased the content of CD4+/CD8+and NK cell(%)in peripheral blood.Conclusion SJC has significant immunomodulatory effect and shows significant therapeutic effect on pneumonia model rats by decreasing the content of B cell(%),CD8+(%),IL-1α,IL-1β,IL-2,IL-10,TNF-α,IFN-α,IFN-γ,IgM,and IgG,reducing the weight of thymus,spleen and lung,and increasing the content of CD4+/CD8+and NK cell(%)in peripheral blood.
作者
马莉
黄妍
侯衍豹
张冬冬
张言朋
刘静
张铁军
MA Li;HUANG Yan;HOU Yanbao;ZHANG Dongdong;ZHANG Yanpeng;LIU Jing;ZHANG Tiejun(Tianjin Institute of Pharmaceutical Research Drug Safety Assessment Co.,Ltd.,Tianjin 300301,China;National&Local United Engineering Laboratory of Modern Preparation and Quality Control Technology of Traditional Chinese Medicine,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China;Tianjin Key Laboratory of Quality Marker of Traditional Chinese Medicine,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China;Anhui Jiren Pharmaceutical Co.,Ltd.,Bozhou 236800,China)
出处
《药物评价研究》
CAS
2019年第9期1763-1768,共6页
Drug Evaluation Research
基金
国家中药标准化专项资助(ZYBZH-C-AH-02)
国家自然科学基金资助项目(81430096)
国家自然科学基金资助项目(81703802)